Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson Sells 36,825 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Rating) CEO Christopher Gibson sold 36,825 shares of the firm’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $9.49, for a total transaction of $349,469.25. Following the completion of the transaction, the chief executive officer now directly owns 541,829 shares of the company’s stock, valued at approximately $5,141,957.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Christopher Gibson also recently made the following trade(s):

  • On Thursday, July 7th, Christopher Gibson sold 37,114 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.05, for a total transaction of $335,881.70.
  • On Thursday, June 2nd, Christopher Gibson sold 39,690 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $6.09, for a total transaction of $241,712.10.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded up $0.31 during trading on Friday, reaching $9.91. 640,317 shares of the company traded hands, compared to its average volume of 1,086,274. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.92 and a 1-year high of $31.43. The company has a 50 day moving average price of $7.92 and a 200-day moving average price of $8.10. The firm has a market capitalization of $1.69 billion, a PE ratio of -7.43 and a beta of -0.48.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Rating) last released its earnings results on Tuesday, May 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.84). Recursion Pharmaceuticals had a negative net margin of 1,635.19% and a negative return on equity of 37.18%. The company had revenue of $5.33 million for the quarter, compared to analyst estimates of $152.90 million. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on RXRX. Bank of America lowered shares of Recursion Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $10.00 target price on the stock. in a report on Monday, April 18th. The Goldman Sachs Group cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 24th.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of RXRX. CWM LLC purchased a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at about $37,000. Itau Unibanco Holding S.A. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $44,000. Daiwa Securities Group Inc. increased its stake in Recursion Pharmaceuticals by 41.6% in the 1st quarter. Daiwa Securities Group Inc. now owns 7,241 shares of the company’s stock valued at $52,000 after buying an additional 2,127 shares during the last quarter. Evoke Wealth LLC purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $77,000. Finally, Centaurus Financial Inc. purchased a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at about $82,000. 55.25% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Featured Stories

Insider Buying and Selling by Quarter for Recursion Pharmaceuticals (NASDAQ:RXRX)

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.